Association between adiponectin, resistin, insulin resistance, and colorectal tumors

Gönüllü, Güzin; Kahraman, Hakkı; Bedir, Abdülkerim; Bektaş, Ahmet; Yücel, İdris

doi:10.1007/s00384-009-0828-6

Cited by 89 publications

(81 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reduced circulatory levels of adiponectin have been shown in obese patients and implicated in the development of obesity-related malignancy (Yang et al, 2002;Cnop et al, 2003). Low ApN levels were found in breast, endometrial, prostate, colon and gastric cancers (Mantzoros et al, 2004;Ishikawa et al, 2005;Michalakis et al, 2007;Kumor et al;2009;Gonullu et al, 2010;Chen et al, 2012;Gulcelik et al, 2012;Ho et al, 2012). A positive correlation was shown between body-mass index and colorectal cancer in several studies (Murphy et al, 2000;Moore et al, 2004).…”

Section: Association Of Adiponectin Receptor (Adipo-r1/-r2) Expressiomentioning

confidence: 99%

Association of Adiponectin Receptor (Adipo-R1/-R2) Expression and Colorectal Cancer

Ayyildiz

Dolar²,

Uğraş³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Association Of Adiponectin Receptor (Adipo-r1/-r2) Expressiomentioning

confidence: 99%

Association of Adiponectin Receptor (Adipo-R1/-R2) Expression and Colorectal Cancer

Ayyildiz

Dolar²,

Uğraş³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Aside from treatment possibilities, adiponectin is a good biomarker for colorectal adenoma patients due to its significant inverse correlation with the number of adenomas [73]. Additionally, low adiponectin levels are associated with insulin resistance as well as stage of colorectal cancer, indicating that low adiponectin is connected to poor prognosis and possibly carcinogenesis [74]. Furthermore, in both human and mouse colon cancer cell lines adiponectin and Metformin combined reversed the effect of IL-1β, an inducer of cancer carcinogenesis via tumor suppressor protein p53 [75].…”

Section: Adiponectinmentioning

confidence: 99%

Adipose tissue, obesity and adipokines: role in cancer promotion

Booth

Magnuson

Fouts

et al. 2015

Hormone Molecular Biology and Clinical Investigation

250

235

View full text Add to dashboard Cite

Adipose tissue is a complex organ with endocrine, metabolic and immune regulatory roles. Adipose depots have been characterized to release several adipocytokines that work locally in an autocrine and paracrine fashion or peripherally in an endocrine fashion. Adipocyte hypertrophy and excessive adipose tissue accumulation, as occurs during obesity, dysregulates the microenvironment within adipose depots and systemically alters peripheral tissue metabolism. The term "adiposopathy" is used to describe this promotion of pathogenic adipocytes and associated adipose -elated disorders. Numerous epidemiological studies confirm an association between obesity and various cancer forms. Proposed mechanisms that link obesity/adiposity to high cancer risk and mortality include, but are not limited to, obesity-related insulin resistance, hyperinsulinemia, sustained hyperglycemia, glucose intolerance, oxidative stress, inflammation and/or adipocktokine production. Several epidemiological studies have demonstrated a relationship between specific circulating adipocytokines and cancer risk. The aim of this review is to define the function, in normal weight and obesity states, of wellcharacterized and novel adipokines including leptin, adiponectin, apelin, visfatin, resistin, chemerin, omentin, nesfatin and vaspin and summarize the data that relates their dysfunction, whether associated or direct effects, to specific cancer outcomes. Overall research suggests most adipokines promote cancer cell progression via enhancement of cell proliferation and migration, inflammation and anti-apoptosis pathways, which subsequently can prompt cancer metastasis. Further research and longitudinal studies are needed to define the specific independent and additive roles of adipokines in cancer progression and reoccurrence.

show abstract

“…Recent studies have shown an association between low plasma levels and/or tissue expression of adiponectin, along with an increased risk of various malignancies for which there is an established association with increased body weight and/or insulin resistance including breast (Miyoshi et al 2003;Mantzoros et al 2004), endometrial (Petridou et al 2003;Cust et al 2007), colorectal (Wei et al 2005;Yoneda et al 2008;Barresi et al 2009;Byeon et al 2010;Gonullu et al 2010), renal (Spyridopoulos et al 2007), and prostate (Mistry et al 2006) cancers, as well as leukemia (Molica et al 2009). …”

mentioning

confidence: 99%

Expression of Adiponectin Receptor 1 Is Indicative of Favorable Prognosis in Non-small Cell Lung Carcinoma

Abdul‐Ghafar

Park

et al. 2013

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Lung cancer is a major cause of cancer-related death worldwide. It is believed that obesity-related malignancies such as breast, endometrial, colorectal, and kidney carcinomas have lower plasma level and/ or tissue expression of adiponectin receptors. However, the association between adiponectin receptors and lung cancer, a non obesity-related malignancy, is still unknown. We evaluated the tissue expression of adiponectin receptor (AdipoR) 1 and AdipoR2 in 83 cases of non-small cell lung carcinoma (NSCLC) and matched non-neoplastic lung tissues by immunohistochemistry and real-time polymerase chain reaction (PCR). Clinicopathological data, including smoking history, smoker's bronchiolitis, emphysema, lymph node metastasis, and T-stage were collected and evaluated. Expression of immunohistochemically stained AdipoR1 and AdipoR2 was observed in all samples of non-neoplastic lung tissues. Both receptors showed higher mRNA expression in non-neoplastic than neoplastic tissues ( p < 0.05). In NSCLC tissues, AdipoR1 immunohistochemical expression was not observed in most of patients with squamous cell carcinoma and current smoking history (31/42, p = 0.04 and 25/29, p = 0.003, respectively). Additionally, AdipoR1 mRNA expression was significantly lower in patients with lymph node metastasis ( p = 0.05). Meanwhile, AdipoR2 immunohistochemical stain expression was inversely correlated with T-stage ( p = 0.05) and AdipoR2 mRNA expression was significantly lower in patients with smoker's bronchiolitis ( p = 0.01) and emphysema ( p = 0.03). Patients with expression of AdipoR1 had longer overall survival. AdipoR2 expression was not correlated with patients' survival. In conclusion, we suggest that expression of AdipoR1 is indicative of favorable prognosis and may be used as prognostic marker in NSCLC.

show abstract

Association between adiponectin, resistin, insulin resistance, and colorectal tumors

Cited by 89 publications

References 43 publications

Association of Adiponectin Receptor (Adipo-R1/-R2) Expression and Colorectal Cancer

Association of Adiponectin Receptor (Adipo-R1/-R2) Expression and Colorectal Cancer

Adipose tissue, obesity and adipokines: role in cancer promotion

Expression of Adiponectin Receptor 1 Is Indicative of Favorable Prognosis in Non-small Cell Lung Carcinoma

Contact Info

Product

Resources

About